- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03721055
Fluoroglutamine PET/CT in Imaging Patients With Malignant Tumor
September 5, 2019 updated by: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
18F-(2S,4R)4-Glutamine PET/CT in Imaging Patients With Malignant Tumor
This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-(2S,4R)4-fluoroglutamine, a glutamic acid derivative, to image patients with malignant tumor.
[18F]Fluoroglutamine PET may provide additional information that help diagnose and stage cancer patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hui Wang, MD
- Phone Number: 86-02125078590
- Email: wanghauishanghai@hotmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200092
- Recruiting
- Xinhua Hospital
-
Contact:
- Hui Wang, MD
- Phone Number: 86-02125078590
- Email: wanghauishanghai@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 79 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age between 18-79;
- The patient must be able to give informed consent;
- Patients can finish PET/CT scan without tranquilizers;
- Patients with pathology-proven cancer or a tumor highly suspected to be malignant ;
- Lesions can be measured and assessed at the RECIST 1.1 standard;
- No chemotherapy, radiotherapy or immune/biologic therapy,or biopsy were allowed between the 18F-FDG and the 4-[18F]Fluoroglutamine PET/CT.
Exclusion Criteria:
- Pregnant or lactating patients;
- Inability or refusal to have at least one peripheral intravenous line for intravenous access;
- From assays obtained <2 weeks prior to study enrollment(ULN:the upper limit of normal value ):Bilirubin>1.5*ULN,AST/ALT >2.5 * ULN, Albumin< 3 g/dl, GGT > 2.5 x ULN if ALP> 2.5 x ULN, Creatinine>1.5*ULN or creatinine clearance <60ml/min;
- Patients with a history of allergic reaction to this drugs or its analogues;
- patients with poor compliance;
- Acute major illness
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 4-[18F]Fluoroglutamine
Patients undergo 18F-FDG PET/CT scan first.
Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
|
Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diagnosing and Staging ability of 4-[18F]Fluoroglutamine PET/CT in malignant cancer
Time Frame: up to three years
|
Sensitivity, specificity, diagnostic accuracy of 4-[18F]Fluoroglutamine and 18F-FDG PET/CT will be compared using paired t-test or Krusal-Wallis test.
|
up to three years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: up to 30 days after the F-Gln imaging
|
The evaluation of the Incidence of Treatment-Emergent Adverse Events starts from the day of F-Gln examination until 30 days later; Treatment-Emergent Adverse Events are evaluated according to version 4.03 CTC-AE criteria.
|
up to 30 days after the F-Gln imaging
|
ASCT2 expression levels in tissue samples
Time Frame: up to three years
|
Wilcoxon rank-sum or Kruskal-Wallis tests will be applied for the group comparisons of IHC staining(ASCT2)
|
up to three years
|
The correlation between 18F-(2S,4R)4- glutamine PET/CT imaging and prognosis in malignant tumors
Time Frame: up to three years
|
Evaluating the prognostic value of metabolic parameters and clinical indexes by using log-rank tests on univariate analysis and COX proportional hazards regression tests
|
up to three years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 21, 2017
Primary Completion (Anticipated)
December 31, 2019
Study Completion (Anticipated)
December 31, 2019
Study Registration Dates
First Submitted
October 24, 2018
First Submitted That Met QC Criteria
October 24, 2018
First Posted (Actual)
October 26, 2018
Study Record Updates
Last Update Posted (Actual)
September 6, 2019
Last Update Submitted That Met QC Criteria
September 5, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XHEC-C-2017-029-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on 18F-(2S,4R)4-fluoroglutamine
-
Xinhua Hospital, Shanghai Jiao Tong University...Shanghai Institute of Materia Medica, Chinese Academy of SciencesUnknownLung Cancer | Cigarette Smoking Behavior | Solitary Pulmonary NoduleChina
-
University of PennsylvaniaRecruiting
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Solid MalignancyUnited States
-
Lexicon PharmaceuticalsCompletedHealthy | Renal ImpairmentUnited States
-
SanofiTerminated
-
Lexicon PharmaceuticalsCompletedHealthyUnited States
-
Alessandro DoriaUniversity of Colorado, Denver; University Health Network, Toronto; University... and other collaboratorsNot yet recruitingHeart Failure | Diabetic Nephropathies | Kidney Failure, Chronic | Diabetes Mellitus Type 1Canada, United States
-
Lexicon PharmaceuticalsSanofiTerminatedHeart Failure | Chronic Kidney Diseases | Type 2 Diabetes MellitusEstonia, Belgium, Sweden, Italy, China, United States, Canada, Bulgaria, Chile, Denmark, Hungary, Latvia, Mexico, Russian Federation, Serbia, Spain, Portugal, Romania, Turkey, Poland, Lithuania, Argentina, Australia, Brazil, Czechia, France, Georg... and more
-
Lexicon PharmaceuticalsSanofiTerminatedHeart Failure | Type 2 Diabetes MellitusBelgium, Canada, Israel, Spain, Germany, Argentina, Chile, Hungary, Korea, Republic of, Latvia, Lithuania, Russian Federation, Sweden, Romania, Poland, Brazil, Denmark, United States, Australia, Austria, Czechia, Finland, France, Greece, Ita... and more
-
SanofiCompletedType 2 Diabetes Mellitus | Healthy SubjectsUnited States